CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15,436 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01079195
NCT01079195N/ACompleted

Effectiveness and Tolerability of Tarka in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus, Not Controlled on Single-drug Therapy: A Multicountry, Multicenter, Post-marketing Observational Study in the Routine Clinical Use

Abbott·observational·Posted Mar 3, 2010·Updated May 9, 2011

In Brief

An observational study for Hypertension. Completed, enrolled 15,436 participants across 898 sites in 7 countries.

Detailed Summary

The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a community setting and in accordance with the terms of the local marketing authorization. The following specific questions will be addressed: * Effectiveness of Tarka in lowering the blood pressure in hypertensive patients being at high risk of developing diabetes, not controlled on single-drug therapy. * Tolerability of Tarka as assessed by withdrawal rates.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesBulgaria, Czechia, Romania, Russia, Slovakia, Slovenia, Ukraine
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 3, 2010
Enrollment StartOct 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.3 years ago